Vincenzo De Falco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7305486/publications.pdf

Version: 2024-02-01

1040056 996975 21 276 9 15 citations h-index g-index papers 21 21 21 440 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	How we treat metastatic colorectal cancer. ESMO Open, 2019, 4, e000813.	4.5	49
2	Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. Cancers, 2019, 11, 1504.	3.7	36
3	Optimal treatment strategy for metastatic melanoma patients harboring <i>BRAF-V600</i> mutations. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092521.	3.2	31
4	Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers, 2021, 13, 1941.	3.7	21
5	Baseline IFN- \hat{l}^3 and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. Scientific Reports, 2020, 10, 17626.	3.3	20
6	Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. Journal of Experimental and Clinical Cancer Research, 2019, 38, 236.	8.6	17
7	Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature. ESMO Open, 2019, 4, e000551.	4.5	15
8	Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 15.	8.6	13
9	Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania  Luigi Vanvitelli'. ESMO Open, 2020, 5, e000675.	4.5	11
10	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. Clinical Colorectal Cancer, 2021, 20, 227-235.	2.3	10
11	Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma. International Journal of Molecular Sciences, 2021, 22, 1166.	4.1	10
12	Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210968.	3.2	8
13	Dual inhibition of $TGF\hat{l}^2$ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. Medical Oncology, 2021, 38, 24.	2.5	7
14	Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR. Cancers, 2022, 14, 3053.	3.7	7
15	A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant. Medicine (United States), 2019, 98, e15759.	1.0	6
16	Role of liquid biopsy for thoracic cancers immunotherapy. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 183-199.	0.8	5
17	Light Alcohol Drinking and the Risk of Cancer Development: A Controversial Relationship. Reviews on Recent Clinical Trials, 2020, 15, 164-177.	0.8	4
18	Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. Cancers, 2021, 13, 4036.	3.7	3

#	Article	IF	CITATIONS
19	Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New Results. Journal of Personalized Medicine, 2021, 11, 206.	2.5	2
20	Multiple acquired mutations captured by liquid biopsy in the EGFR addicted metastatic colorectal cancer Clinical Colorectal Cancer, 2021, , .	2.3	1
21	Current Landscape and Open Questions on Adjuvant Therapies in Melanoma. Dermatology Practical and Conceptual, 2021, 11, 2021165S.	0.9	O